Gujarat Kidney IPO: Analyzed
The Gujarat Kidney and Super Speciality IPO, opening for subscription on December 22, 2025, offers 22 million new shares. This ₹250.80 crore offering aims to grow healthcare services in Gujarat. Experts are weighing in on whether this IPO is a good investment opportunity.
Key Points
- Three brokerages (Arihant, SBI, MUFG) see the IPO as “Neutral.”
- The price range is ₹108 to ₹114 per share.
- A minimum investment of ₹14,592 is needed for one lot.
- Funds will be used for hospital acquisitions and expanding services.
- Shares could list on the NSE and BSE around December 30, 2025.
- The company’s growth is based on rising demand for healthcare.
Several investment firms have taken a cautious approach to the Gujarat Kidney IPO. Arihant Capital, SBI Securities, and MUFG Intime India all gave the IPO a “Neutral” rating, suggesting it might not be a strong investment at this time. The IPO offers shares priced between ₹108 and ₹114, meaning a retail investor needs to invest at least ₹14,592 to buy one lot. The company plans to use the money to buy new hospitals and upgrade equipment.
The company’s plans for growth are centered around increasing demand for healthcare. They are expanding their services by acquiring existing hospitals and buying advanced medical technology. Experts believe the company’s strong renal focus and scalable expansion model will lead to stable patient volumes and improved profits over time.
The grey market premium, where unlisted shares trade before the IPO, suggests investors are optimistic, with shares trading at ₹121, a 6.14% premium over the upper price band. This indicates anticipation of a successful listing.
The funds raised from the IPO will be strategically deployed—₹77 crore for acquiring Parekhs Hospital, ₹12.4 crore for Ashwini Medical Centre, and ₹30.09 crore for a new hospital in Vadodara. These acquisitions are seen as key to the company’s growth strategy.
Investing wisely requires careful consideration of all available information.
